Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 5/20 | 0.41 |
| ▸ | NOS1 | P29475 | 5/20 | 0.41 |
| ▸ | NOS2 | P35228 | 5/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | FPR1 | P21462 | 2/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.39 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21859796 | 0.84 | PIM1 (0.41) | HRH4MCHR1PIM1PIM3PIM2 | |
| SCHEMBL22193275 | 0.83 | HRH4 (0.47) | HRH4NOTUMMCHR1HTR3A | |
| SCHEMBL15062000 | 0.80 | PIM1 (0.52) | MCHR1PIM1PIM3PIM2HTR3A | |
| SCHEMBL2424717 | 0.80 | HRH4 (0.45) | HRH4NOTUMMCHR1PIM1PIM3 | |
| SCHEMBL2424720 | 0.80 | HRH4 (0.45) | HRH4NOTUMMCHR1PIM1PIM3 | |
| SCHEMBL21725490 | 0.80 | HRH4 (0.45) | HRH4NOTUMMCHR1PIM1PIM3 | |
| SCHEMBL22193242 | 0.78 | HRH4 (0.44) | HRH4NOTUMDDR1 | |
| SCHEMBL22193241 | 0.78 | HRH4 (0.44) | HRH4NOTUMDDR1 | |
| SCHEMBL22193250 | 0.77 | MAPT (0.42) | NOTUMPIM1PIM3PIM2DDR1 | |
| SCHEMBL26384380 | 0.76 | ELANE (0.39) | HRH4MCHR1PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | HRH4 355/4885NOTUM 4477/4885MCHR1 7/4885 |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | HRH4 355/4885NOTUM 4477/4885MCHR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.